Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-10-05. The firm is engaged in advancing treatments for neurodegenerative diseases. The firm is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
Follow-Up Questions
Neurizon Therapeutics Ltd 的 CEO 是谁？
Dr. Michael Thurn 是 Neurizon Therapeutics Ltd 的 Chief Executive Officer，自 2023 加入公司。
NUZTF 股票的价格表现如何？
NUZTF 的当前价格为 $0，在上个交易日 decreased 了 0%。
Neurizon Therapeutics Ltd 的主要业务主题或行业是什么？
Neurizon Therapeutics Ltd 属于 Pharmaceuticals 行业，该板块是 Health Care
